Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...
A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...
The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing ...
Nutritional compromise in cervical cancer patients undergoing chemoradiotherapy predicts poor survival, increased toxicity, ...
The FDA has granted approval to a larger vial size of nelarabine injection (SH-111) for use in treatment of adult and ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses ...
Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic ...
With a median follow-up of 4.2 years, patients receiving blinatumomab achieved a 4-year disease-free survival (DFS) of 83.3% ...
Abemaciclib improved progression-free survival at 6 months in meningiomas with NF2 or CDK pathway alterations, achieving a 58 ...
The FDA has granted breakthrough therapy designation (BTD) for bezuclastinib in combination with sunitinib (Sutent) for the ...
New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal ...
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results